Combination of oral zinc gluconate and topical triclosan: An anti-inflammatory treatment modality for initial hidradenitis suppurativa

Hessam, Schapoor; Sand, Michael; Meier, Nina M.; Gambichler, Thilo; Scholl, Lisa; Bechara, Falk G.

doi:10.1016/j.jdermsci.2016.08.010

Cited by 52 publications

(39 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…185 A retrospective study of 54 patients with Hurley stage I or II disease who were treated with zinc gluconate, 90 mg daily, and topical triclosan 2% for 3 months demonstrated improvement in mean DLQI score (P = .039). 118 Another prospective study of 22 patients receiving 90 mg daily reported improvement in all patients, with 8 complete responses and 14 partial responses. 114 Guillet et al 120 found that of 22 vitamin Dedeficient patients with HS who received supplements to achieve normal levels, 63% achieved a 20% decrease in inflammatory nodules.…”

Section: Lifestyle Factors and Alternative Treatments In Hsmentioning

confidence: 98%

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations

Alikhan

Sayed

Alavi

et al. 2019

Journal of the American Academy of Dermatology

268

382

View full text Add to dashboard Cite

Hidradenitis suppurativa is a chronic inflammatory disorder affecting hair follicles, with profoundly negative impact on patient quality of life. Evidence informing ideal evaluation and management of patients with hidradenitis suppurativa is still sparse in many areas, but it has grown substantially in the last decade. Part I of this evidence-based guideline is presented to support health care practitioners as they select optimal management strategies, including diagnostic testing, comorbidity screening, and both complementary and procedural treatment options. Recommendations and evidence grading based on the evidence available at the time of the review are provided.

show abstract

Section: Lifestyle Factors and Alternative Treatments In Hsmentioning

confidence: 98%

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations

Alikhan

Sayed

Alavi

et al. 2019

Journal of the American Academy of Dermatology

268

382

View full text Add to dashboard Cite

show abstract

“…In Hurley stage I/II, the combination of oral zinc gluconate (30 mg thrice daily) and topical triclosan 2% (twice daily) may be considered as a treatment option 44 (evidence level 4, grade of recommendation C).…”

Section: Consensus (100%) [After Revote]mentioning

confidence: 99%

Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group

Zouboulis

Bechara

Dickinson-Blok

et al. 2018

Acad Dermatol Venereol

192

291

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS)/acne inversa is a debilitating chronic disease that remains poorly understood and difficult to manage. Clinical practice is variable, and there is a need for international, evidence-based and easily applicable consensus on HS management. We report here the findings of a systematic literature review, which were subsequently used as a basis for the development of international consensus recommendations for the management of patients with HS. A systematic literature review was performed for each of nine clinical questions in HS (defined by an expert steering committee), covering comorbidity assessment, therapy (medical, surgical and combinations) and response to treatment. Included articles underwent data extraction and were graded according to the Oxford Centre for Evidence-based Medicine criteria. Evidence-based recommendations were then drafted, refined and voted upon, using a modified Delphi process. Overall, 5310 articles were screened, 171 articles were analysed, and 65 were used to derive recommendations. These articles included six randomized controlled trials plus cohort studies and case series. The highest level of evidence concerned dosing recommendations for topical clindamycin in mild disease (with systemic tetracyclines for more frequent/widespread lesions) and biologic therapy (especially adalimumab) as second-line agents (following conventional therapy failure). Good-quality evidence was available for the hidradenitis suppurativa clinical response (HiSCR) as a dichotomous outcome measure in inflammatory areas under treatment. Lower-level evidence supported recommendations for topical triclosan and oral zinc in mild-to-moderate HS, systemic clindamycin and rifampicin in moderate HS and intravenous ertapenem in selected patients with more severe disease. Intralesional or systemic steroids may also be considered. Local surgical excision is suggested for mild-to-moderate HS, with wide excision for more extensive disease. Despite a paucity of good-quality data on management decisions in HS, this systematic review has enabled the development of robust and easily applicable clinical recommendations for international physicians based on graded evidence.

show abstract

“…38,39 There were five publications on surgical treatment, [40][41][42][43][44] one study on combination of surgical treatment with photodynamic therapy 45 and two other studies on photodynamic therapy. 46,47 There were three studies on antibiotics, [48][49][50] single studies on metformin, 51 PUVA, 52 hyperbaric oxygen therapy, 53 alitretinoin, 54 acitretin, 55 ankinra, 56 apremilast, 57 oral zinc gluconate combined with topical triclosan 58 and verapamil. 59 Detailed information on clinical trials that included ten or more HS patients is presented in Table 1.…”

Section: Clinical Trials In Hsmentioning

confidence: 99%

Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient‐Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

Chernyshov

Zouboulis

Tómas-Aragonés

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

This paper is organized jointly by the European Academy of Dermatology and Venereology (EADV) Task Force (TF) on Quality of Life (QoL) and Patient‐Oriented Outcomes and the EADV TF on acne, rosacea and hidradenitis suppurativa (ARHS). The purpose of this paper was to present current knowledge about QoL assessment in HS, including data on HS‐specific health‐related (HR) QoL instruments and HRQoL changes in clinical trials, and to make practical recommendations concerning the assessment of QoL in people with HS. HS results in significant quimp that is higher than in most other chronic skin diseases. HS impact in published studies was assessed predominantly (84% of studies) by the Dermatology Life Quality Index (DLQI). There is a lack of high‐quality clinical trials in HS patients where HRQoL instruments have been used as outcome measures. One double‐blind randomized placebo‐controlled trial on infliximab with low number of participants reported significantly better HRQoL improvement in the treatment group than in the placebo group. Well‐designed clinical studies in HS patients to compare different treatment methods, including surgical methods and assessing long‐term effects, are needed. Because of lack of sufficient validation, the Task Forces are not at present able to recommend existing HS‐specific HRQoL instruments for use in clinical studies. The EADV TFs recommend the dermatology‐specific DLQI questionnaire for use in HS patients. The EADV TFs encourage the further development, validation and use of other HS‐specific, dermatology‐specific and generic instruments but such use should be based on the principles presented in the previous publications of the EADV TF on QoL and Patient‐Oriented Outcomes.

show abstract

Combination of oral zinc gluconate and topical triclosan: An anti-inflammatory treatment modality for initial hidradenitis suppurativa

Cited by 52 publications

References 36 publications

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations

Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group

Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient‐Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

Contact Info

Product

Resources

About